Evogene (NASDAQ:EVGN – Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09, MarketWatch Earnings reports. Evogene had a negative net margin of 354.35% and a negative return on equity of 64.44%. The company had revenue of $3.77 million for the quarter, compared to analysts’ expectations of $1.09 million. During the same quarter in the prior year, the firm earned ($0.16) EPS.
Evogene Stock Down 0.9 %
EVGN traded down $0.01 during trading on Friday, reaching $0.66. 53,729 shares of the company were exchanged, compared to its average volume of 172,521. The company has a market cap of $27.20 million, a price-to-earnings ratio of -1.37 and a beta of 1.38. Evogene has a 12-month low of $0.45 and a 12-month high of $1.44. The company’s 50-day moving average is $0.58 and its two-hundred day moving average is $0.75.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SNC raised its stake in shares of Evogene by 265.4% during the second quarter. BNP Paribas Arbitrage SNC now owns 26,700 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 19,393 shares in the last quarter. Virtu Financial LLC purchased a new position in Evogene in the 1st quarter worth $48,000. Vident Investment Advisory LLC lifted its stake in Evogene by 68.5% in the first quarter. Vident Investment Advisory LLC now owns 83,868 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 34,082 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Evogene by 31.8% during the first quarter. Renaissance Technologies LLC now owns 118,193 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 28,493 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Evogene by 49.7% in the first quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 67,867 shares in the last quarter. 1.71% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
- Five stocks we like better than Evogene
- How to Invest in Electric Cars
- 3 large caps with red hot RSIs with upside
- How to Invest in Hotel Stocks
- Johnson Controls International: Nothing but upside for investors
- Dividend Capture Strategy: What You Need to Know
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.